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Abstract
Background: Monocyte-derived-dendritic-cells (MDDC) are the major DC type used in vaccine-
based clinical studies for a variety of cancers. In order to assess whether in vitro differentiated
MDDC from cryopreserved PBMC of cancer patients are functionally distinct from those of healthy
donors, we compared these cells for their expression of co-stimulatory and functional markers. In
addition, the effect of cryopreservation of PBMC precursors on the quality of MDDC was also
evaluated using samples from healthy donors.
Methods: Using flow cytometry, we compared normal donors and cancer patients MDDC grown
in the presence of GM-CSF+IL-4 (immature MDDC), and GM-CSF+IL-4+TNFα+IL-1β+IL-6+PGE-
2 (mature MDDC) for (a) surface phenotype such as CD209, CD83 and CD86, (b) intracellular
functional markers such as IL-12 and cyclooxygenase-2 (COX-2), (c) ability to secrete IL-8 and IL-
12, and (d) ability to stimulate allogeneic and antigen-specific autologous T cells.
Results: Cryopreservation of precursors did affect MDDC marker expression, however, only two
markers, CD86 and COX-2, were significantly affected. Mature MDDC from healthy donors and
cancer patients up-regulated the expression of CD83, CD86, frequencies of IL-12+ and COX-2+
cells, and secretion of IL-8; and down-regulated CD209 expression relative to their immature
counterparts. Compared to healthy donors, mature MDDC generated from cancer patients were
equivalent in the expression of nearly all the markers studied and importantly, were equivalent in
their ability to stimulate allogeneic and antigen-specific T cells in vitro.
Conclusion: Our data show that cryopreservation of DC precursors does not significantly affect
the majority of the MDDC markers, although the trends are towards reduced expression of co-
stimulatory makers and cytokines. In addition, monocytes from cryopreserved PBMC of cancer
patients can be fully differentiated into mature DC with phenotype and function equivalent to those
derived from healthy donors.
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Background
Dendritic cells (DC) are promising vehicles for immuno-
therapy because they are efficient in capturing, processing,
and presenting antigens to both naive and memory CD4
and CD8 T cells [1]. To induce strong, antigen-specific T
cell responses, DC must mature and express high levels of
MHC-antigen complexes and co-stimulatory molecules
that enhance interactions with T cells. As a therapeutic
modality, the low frequency of DC makes it difficult to
readily utilize their unique properties to facilitate innate
as well as adaptive immunity. In recent years, major
advances have been made in the identification of DC pre-
cursors and methods to expand and manipulate these
cells ex vivo. Thus, significant efforts have been made to
utilize cultured DC pulsed with tumor antigens (DC vac-
cines) to induce anti-tumoral immunity [2-4]. The studies
performed to evaluate whether autologous DC precursors
from cancer patients are functionally equivalent to those
from healthy donors report a defective, semi-differenti-
ated, or intermediate mature phenotype of DC derived
from fresh PBMC of cancer patients [5-7]. Furthermore,
there are several reports indicating that the cryopreserva-
tion of MDDC does not interfere with their activity when
compared to freshly derived MDDC from healthy donors
as well as cancer patients [8-10]. Although for therapeutic
use, generation of DC from cryopreserved PBMC would
appear to be an efficient source of precursors, there are
very few reports studying the effect of cryopreservation of
PBMC precursors on the phenotype and function of
MDDC[11,12]. To test the hypothesis that the phenotypic
and functional characteristics of MDDC derived from cry-
opreserved PBMC of cancer patients are different from
those derived from healthy donors, we evaluated qualita-
tive and quantitative differences between DC generated
from both sources. In addition, the effect of cryopreserva-
tion of precursors on the characteristics of MDDC was
also evaluated. Specifically, using flow cytometry-based
assays, we compared the surface expression of DC-SIGN
(CD209), CD83, CD86, and HLA-DR, intracellular
expression of IL-12 and COX-2, secretion of inflammatory
cytokines, and proliferation of allogeneic and antigen-
specific autologous T cells stimulated in vitro by DC.
Defective antigen-presenting-cell (APC) function may be
associated with impaired HLA expression and lack of co-
stimulatory molecules. This is perceived to be one of the
primary mechanisms by which tumors evade immune
surveillance[7,13,14]. CD83, CD86 and HLA-DR are mat-
uration and co-stimulatory markers expressed on the sur-
face of mature DC activated by various stimuli [15,16].
Up-regulation of HLA-DR and CD86 enable DC to inter-
act more efficiently with T cells and stimulate immune
responses. Conversely, the C-type lectin, DC-SIGN
(CD209), which is widely recognized as a myeloid DC-
specific marker, is down-regulated on DC as a result of
maturation [17,18]. The cytokine repertoire of DC
matured in the presence of inflammatory stimuli com-
prises pro-inflammatory cytokines and chemokines,
including the T cell inhibitory cytokine IL-10, the Th-1
promoting cytokine IL-12, as well as TNF-α and IL-8 [19-
23]. In addition, cyclooxygenase-2 (COX-2), an enzyme
responsible for converting arachidonic acid to prostaglan-
din-E2 (PGE-2), is induced in response to inflammatory
stimuli and results in the production of immunosuppres-
sive and pro-inflammatory prostanoids [24-27]. Ability to
produce COX-2 can be used as a functional marker of
inflammation.
In the present report, MDDC were cultured from fresh and
cryopreserved PBMC of healthy donors and cryopreserved
PBMC of cancer patients. A comparison of mature MDDC
derived from cryopreserved PBMC of the cancer patients
and healthy donors revealed that MDDC from cancer
patients manifested equivalent levels of expression of vir-
tually all the biomarkers studied including their ability to
stimulate T cells.
Methods
Donor characteristics
Blood samples from all the donors used in this study were
collected after obtaining IRB approvals and appropriate
informed consent. Leukapheresis of 16 cancer patients
and 11 healthy donors was approved by the IRB of Uni-
versity of Washington (Seattle, WA) and Duke University
Medical Center (Durham, NC); PBMC from these samples
were prepared using Ficoll-hypaque (Sigma, St. Louis,
MO) density gradient separation of leukapheresis prod-
ucts, and processed for cryopreservation [28]. The cancer
patient cohort consisted of subjects with advanced cancers
of breast, colon, and lung (Table 1). The median age of
cancer patients (12 females and 4 males) was 56.5 ± 8.5
yrs. and the median age of the 8 female and 3 male
healthy donors was 26 ± 4.5 yrs. For studies with fresh
PBMC, blood was collected from 11 in-house healthy
donors (3 females and 8 males) in Vacutainer® CPT™ (Cell
Preparation Tubes, BD Vacutainer, Franklin Lakes, NJ).
The median age of the healthy donors (fresh) was 45 ± 7
yrs. The study was performed retrospectively. Therefore,
fresh and cryopreserved samples from the same healthy
donors or cancer patients were not available for direct
comparison. Neither of the healthy donor control groups
was specifically intended to be age or gender-matched
with the patient group. Although MDDC were generated
from all 16 patients, because of the limited yields, samples
from all the patients were not used for evaluation in all
the assays.
Generation of MDDC cultures
MDDC were generated as described previously [29] with
some modifications. In brief, PBMC were adhered to PetriJournal of Immune Based Therapies and Vaccines 2007, 5:7 http://www.jibtherapies.com/content/5/1/7
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dishes (BD Falcon, Bedford, MA) for 60 min at 37°C, and
the adherent cells were cultured in complete medium
[RPMI 1640 (Sigma) supplemented with 1% heat-inacti-
vated plasma, and containing rh-GM-CSF (1000 units/ml,
R&D Systems, Minneapolis, MN) and rh-IL-4 (800 units/
ml, R&D Systems)]. Cultures were fed with complete
medium every other day. On day five, the cultures were
split into 6-well plates. On day six, a maturation cocktail
consisting of rh-TNF-α, rh-IL-1β, rh-IL-6 (each at 10 ng/
mL, R&D Systems), and PGE-2 (1 μg/mL, Sigma) in com-
plete medium was added to half the wells (mature
MDDC); the cells from the remaining wells received com-
plete medium alone (immature MDDC). Twenty-four
hours later, the non-adherent cells from each group were
collected and used for analysis. The culture supernatants
were stored at -80°C for assessment of secreted cytokines.
Surface staining of MDDC for phenotypic analysis
Immature and mature MDDC were stained with CD14- or
HLA-DR-FITC, CD86-PE, CD209-PerCP-Cy5.5, and
CD83-APC (BD Biosciences, San Jose, CA) for 30 minutes
in dark at room temperature. The cells were then washed
with PBS containing 1% BSA and 0.1% sodium-azide
(wash buffer), fixed in 1% paraformaldehyde, and stored
at 4°C in the dark. The samples were analyzed on a FAC-
SCalibur™ flow cytometer (BD Biosciences) within 24 h.
Detection of intracellular IL-12 and COX-2 by flow 
cytometry
MDDC collected from day 7 cultures were stimulated in
the presence of a secretion inhibitor, brefeldin-A (BFA, 5
μg/mL, Sigma) for 18–20 h in 96-well polypropylene V-
bottom plates (BD Falcon) without or with LPS (100 ng/
mL, Sigma), or with rh-IFN-γ (1000 U/mL, R&D Systems)
+ LPS. Cells were washed and surface stained with CD209-
PerCP-Cy5.5 and CD14-FITC (BD Biosciences), followed
by fixation and permeabilization (Cytofix/Cytoperm
solution, BD Biosciences, San Diego, CA). The cells were
then stained with PE or APC conjugated anti-IL-12 and PE
conjugated anti-COX-2 mAbs (BD Biosciences). The
washed and fixed samples were stored at 4°C in the dark
and analyzed on a FACSCalibur flow cytometer within 24
h.
Detection of secreted cytokines by Cytometric Bead Array 
(CBA)
For detection of secreted cytokines, supernatants from
immature and mature MDDC cultures were thawed and
analyzed with the Human Inflammation CBA kit (BD Bio-
sciences, San Diego, CA) according to the manufacturer's
instructions. Cytokines that had been added to the cul-
tures for maturation (GM-CSF, IL-1β, IL-6, and TNF-α)
were excluded from further analysis.
Allogeneic and antigen-specific autologous T cell 
stimulation
MLR were performed to test the ability of DC to stimulate
allogeneic T cells. PBMC from fresh blood of healthy
donors were labeled with 5 μM final concentration of
CFSE (Vybrant CFDA-SE Cell Tracer Kit, Molecular
Probes, Eugene, OR) for 15 minutes at 37°C. Labeled cells
were washed according to manufacturer's instructions and
used as responder cells. Mature MDDC from healthy
donors and cancer patients were plated at 1 to 2 × 105
cells/well in a 24-well plate (BD Falcon) in RPMI with
10% heat-inactivated FBS. CFSE-labeled responder PBMC
were added to the wells containing MDDC at DC:PBMC
ratios of 1:1, 1:5, and 1:20, and the cells were cultured for
four days. On day 4, cells were washed and surface stained
with CD3-PE, CD209 PerCP-Cy5.5, and CD4-APC (BD
Biosciences) as described above. Proliferation was meas-
ured as percentage of CD3+CD4+ and CD3+CD4- (from
Table 1: 
Patient ID Sex Type of Cancer/stage
PH6272 F Breast/3b
JLN2159 F Breast/4
DMC6393 F Breast/3a
94 F Breast/2
87 F Breast/3b
72 F Breast/1
73 F Breast
74 F Breast/2
A M Colon/4
B M Colon/4
C M Colon/4
D M Colon/4
E F Colon/4
F F Small bowel/4
G F Non small cell lung (NSCLC)
BJH0761 F LungJournal of Immune Based Therapies and Vaccines 2007, 5:7 http://www.jibtherapies.com/content/5/1/7
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here on referred to as CD8+) cells, excluding the CD209+
MDDC (stimulator cells), with decreased CFSE staining
intensity resulting from dilution during cell division (viz.,
the fluorescence intensity of membrane staining halves
with each cell division). Background proliferation of allo-
geneic responder PBMC in the absence of MDDC stimula-
tors was subtracted for data analysis.
Ability of MDDC to enhance superantigen-specific, recall
antigen-specific, and tumor antigen-specific autologous T
cell stimulation was respectively measured by using SEB
(0.25 μg/ml, List Biological Laboratories, Inc., Campbell,
CA), and overlapping peptide mixes of CMV-pp65 (recall
antigen), HER2/neu (intracellular domain), MAGE-3, or
CEA (commonly expressed tumor antigens) as antigenic
stimuli. SEB, a superantigen, was used as generic positive
control antigen because the serological status of the
donors for any of the commonly-used recall antigens was
not known. However, 50%–80% of the adult population
in US is CMV-seropositive[30], suggesting that responses
might be expected in approximately 50%–80% of the sub-
jects surveyed. Similarly, the most commonly-expressed
tumor antigens, e.g., Her-2/neu, MAGE-3 and CEA were
selected to evaluate the ability MDDC to stimulate tumor-
antigen-specific T cells [31-39]. Mixtures of peptides con-
sisting of 15 amino acid residues, overlapping by 11
amino acids each, were designed to span the sequences of
CMV pp65, CEA, MAGE-3, and the intracellular domain
(ICD) of HER-2/neu. Sequences were accessed from Gen-
bank [40,41]. All peptide mixes were obtained from Syn-
Pep (Dublin, CA) and were reconstituted at 100×
concentration in dimethylsulfoxide (DMSO), diluted in
PBS and used at 5 μg/ml/peptide (BD Biosciences). A sub-
optimal concentration of SEB was used to enable the
detection of DC-mediated increase in proliferation. Fresh
autologous PBMC or thawed and overnight rested autolo-
gous PBMC, were labeled with CFSE as described above
and used as responder cells to measure antigen-specific
proliferation. One to 2 × 105 MDDC were pulsed with
each of the antigens (when sufficient cells were available)
for 2 h at 37°C. CFSE-labeled autologous PBMC were
added to the wells containing antigen-pulsed MDDC at a
DC:PBMC ratio of 1:5. PBMC stimulated with these anti-
gens in the absence of pulsed MDDC served as controls.
Cultures were incubated for four days and processed as
described above for MLR. Background proliferation of
autologous responder PBMC in the absence of any stimu-
lus was subtracted for data analysis
Statistical analysis
Data were analyzed using Wilcoxon matched pair test
(paired-nonparametric: e.g., unstimulated versus stimu-
lated, SEB-stimulated versus DC+SEB-stimulated), and
Mann-Whitney test (unpaired-nonparametric: e.g., fresh
versus cryopreserved, healthy versus cancer, and imma-
ture versus mature). Comparisons of yield, morphology,
phenotype, and function were made between fresh
PBMC-derived and cryopreserved PBMC-derived MDDC
of healthy donors, and between cryopreserved PBMC-
derived MDDC of healthy donors and cancer patients.
GraphPad Prism statistical software (GraphPad Software
Version 4.01, San Diego, CA) was used for data analysis
and graphs.
Results
Cryopreservation of DC precursors does not significantly 
affect the majority of the MDDC characteristics
The effect of cryopreservation on the differentiation of DC
was studied by comparing the phenotypic and functional
properties of mature MDDC derived from cryopreserved
PBMC of healthy donors to those from fresh PBMC of
healthy donors. Because PBMC from cancer patients were
only available in a cryopreserved format, these cells were
not available for use in this comparison.
Cryopreservation did not significantly affect levels of cell
surface expression of CD209 (data not shown), CD83,
and HLA-DR (Fig. 1A), or secretion of IL-8 (Fig. 1B). How-
ever, CD86 expression was significantly higher on mature
MDDC derived from cryopreserved versus fresh PBMC
(Fig. 1A).
When intracellular expression of IL-12 was evaluated in
mature MDDC from fresh and cryopreserved PBMC, no
differences were observed in the frequency of IL-12+ cells
in unstimulated (constitutive expression) and LPS-stimu-
lated cultures. Unlike IL-12, cryopreservation of PBMC
decreased the frequency of COX-2+ cells in unstimulated
mature MDDC cultures (Fig. 1B). In addition, significant
increases in COX-2+ cells were observed in LPS and IFN-
γ+LPS stimulated mature MDDC from cryopreserved
PBMC, compared to the mature MDDC from fresh PBMC
(p < 0.03, data not shown).
The ability of mature MDDC derived from fresh and cryo-
preserved PBMC to stimulate allogeneic T cells was
assessed by performing MLR. Mature MDDC prepared
from cryopreserved PBMC were not significantly different
compared to those from fresh PBMC in stimulating allo-
geneic CD4+ (p = 0.063, Fig. 1C, Top panel) and CD8+ (p
= 0.3527, data not shown) T cell proliferation.
When tested for antigen-specific autologous T cell stimu-
latory capacity, mature MDDC derived from both fresh
PBMC as well as cryopreserved PBMC were able to signif-
icantly enhance SEB-specific autologous CD4+ and CD8+
T cell proliferation compared to the stimulation of PBMC
with SEB alone (Fig. 1C, middle and bottom graphs).
Autologous CD4+ and CD8+ T cell stimulation in response
to CMV-pp65, HER2/neu, and MAGE was also higher inJournal of Immune Based Therapies and Vaccines 2007, 5:7 http://www.jibtherapies.com/content/5/1/7
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Comparison of mature MDDC derived from fresh PBMC vs. cryopreserved PBMC of healthy donors Figure 1
Comparison of mature MDDC derived from fresh PBMC vs. cryopreserved PBMC of healthy donors. A. Surface 
phenotype: Mature MDDC derived from fresh or cryopreserved PBMC were stained with antibodies to CD209, CD86, CD83, 
and HLA-DR as described in Methods. For flow cytometric analysis, a gate was set on the cells with large scatter (size) that 
were expressing the myeloid DC specific marker CD209. The staining intensities (mean fluorescence intensity, MFI) of CD86, 
CD83, and HLA-DR were compared between mature MDDC derived from fresh or cryopreserved PBMC. B. Functional 
markers: Mature MDDC derived from fresh or cryopreserved PBMC were cultured for additional 18–20 h in presence of 
secretion inhibitor BFA. As described in Methods, cells were surface stained with antibodies to CD209, CD14, or CD86, and 
stained with antibodies to IL-12 and COX-2 for intracellular detection. For flow cytometric analysis, a gate was set on the large 
cells that also expressed CD209. Results are expressed as percentage of CD209+ cells that were positive for IL-12 
(%CD209+IL-12+) or COX-2 (%CD209+COX-2+). Amounts of IL-8 (pg/ml) secreted by mature MDDC from each group were 
detected by using Cytometric Bead Array (CBA) technology (see Methods). Reported quantities (pg/ml) of the cytokines and 
chemokines reflect the production by 5 × 105 cells cultured in 3.75 ml medium. C. T cell stimulation: Scatter plot in the top 
panel shows proliferation of allogeneic CD4+ T cells using mature MDDC from fresh and cryopreserved PBMC of healthy 
donors. One to 2 × 105 MDDC were mixed with CFSE-labeled allogeneic fresh PBMC at a DC:PBMC ratio of 1:5 in a total vol-
ume of 1 ml/well of a 24-well plate. The lower two scatter plots demonstrate enhancement of MDDC mediated SEB-specific 
autologous CD4+ and CD8+ T cell proliferation. CFSE-labeled autologous PBMC from either fresh or cryopreserved healthy 
donors were added to the wells containing SEB alone or SEB-pulsed respective autologous mature MDDC at a DC:PBMC ratio 
of 1:5 as described in Methods. After four days of culture, cells were surface stained with CD3 PE, CD209 PerCP-Cy5.5 and 
CD4 APC and acquired on a flow cytometer. CD3+CD4+ lymphocytes were gated including the blasts and excluding CD209+ 
MDDC. The percentage of cells showing decreased CFSE staining intensity was reported as %proliferation. Bars in all the scat-
ter plots represent medians. *, statistically significant differences (P < 0.05); **, statistically significant differences (P < 0.01).
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the presence of MDDC from the cryopreserved healthy
group compared to the stimulation of PBMC with these
antigens alone. However, when DC were derived from
fresh PBMC, the antigen-specific, DC-driven responses
were comparable to those achieved with antigen alone
(data not shown). This difference appears to be the result
of diminished antigen-specific baseline responses, poten-
tially associated with compromised APC function in cryo-
preserved PBMC. Addition of antigen-pulsed MDDC to
these cultures appears to increase the baseline responses.
When efficiency of autologous T cell stimulation was
compared between fresh PBMC-derived and cryopre-
served PBMC-derived MDDC, there were no statistically
significant differences between antigen-specific (SEB,
CMV-pp65, MAGE) CD4+  T cell proliferation (e.g.,
DC+SEB columns of fresh vs. cryo. in the middle graph in
Fig. 1C), with the exception of HER2/neu and CEA where
responses of fresh PBMC-derived samples were higher (p
< 0.05) compared to the cryopreserved samples (data not
shown). There were no significant differences between
any of the antigen-specific responses of CD8+ T cells stim-
ulated by these two different groups of MDDC (e.g., the
DC+SEB columns of fresh vs. cryo. in bottom graph in Fig.
1C).
Monocytes from cryopreserved PBMC of cancer patients 
can differentiate into mature DC
To examine whether the source of precursors (i.e., fresh
healthy PBMC, cryopreserved healthy PBMC, or cryopre-
served cancer PBMC) affected the maturation-induced
changes of MDDC, immature and mature MDDC within
each of the three groups were evaluated for their expres-
sion of surface and other functional markers.
Compared to immature MDDC, a population of mature
MDDC with significantly down-modulated CD209
expression (p < 0.01, not shown), and significantly up-
regulated CD86, CD83, and HLA-DR expression was iden-
tified in all of the three groups (Fig. 2A). Mature MDDC
from all three groups contained significantly higher fre-
quencies of IL-12+ cells without further re-stimulation,
when compared to the respective immature MDDC (Fig.
2B, top panel). As shown in Fig. 2B (middle panel),
unstimulated mature MDDC cultures from fresh healthy
and cryopreserved cancer groups contained significantly
higher numbers of COX-2+ cells compared to the corre-
sponding unstimulated immature MDDC.
Both immature and mature MDDC from fresh PBMC of
healthy donors and cryopreserved PBMC of cancer
patients responded to LPS stimulation by displaying a sig-
nificantly higher frequency of IL-12+ and COX-2+cells,
compared to the corresponding unstimulated cells (p <
0.05, data not shown). The dot plots in Fig. 3A and 3B
show the intracellular staining profiles of IL-12 and COX-
2 in unstimulated and IFNγ+LPS-stimulated immature
MDDC derived from fresh PBMC.
In all three groups studied, mature MDDC secreted signif-
icantly higher amounts of IL-8 compared to the corre-
sponding immature MDDC (Fig. 2B, bottom panel).
There were no significant differences in IL-10 and IL-12
secretion when the supernatants from immature MDDC
cultures were compared to those from mature MDDC
within each group (data not shown).
None of the variables described in the preceding para-
graphs of this section, however, correlated with the ability
of mature MDDC to stimulate in MLR or antigen-specific
autologous T cell stimulation (data not shown).
Characteristics of mature MDDC from cancer patients are 
equivalent to those from healthy donors
To determine whether there were differences between the
characteristics of MDDC from cancer patients and healthy
donors, the phenotypes and functions of these cells were
directly compared. Because only cryopreserved PBMC
from cancer patients were available, this group was com-
pared to cryopreserved PBMC-derived MDDC from
healthy donors.
There were no significant differences in the expression lev-
els of CD209 (not shown) and CD86 on mature MDDC
when cultures derived from cancer patients were com-
pared to cultures from healthy donors (Fig. 4A). Signifi-
cantly higher expression levels of CD83 and HLA-DR,
however, were observed on mature MDDC from cancer
patients compared to those from healthy donors (Fig. 4A).
Small but significant increases in IL-12+  cells were
observed in mature MDDC derived from the cancer
patients as compared to those from healthy donors (Fig.
4B). However, mature MDDC cultures derived from
healthy donors and cancer patients contained equivalent
frequencies of COX-2+  cells (Fig 4B, middle panel).
Mature MDDC from cancer patients as well as from
healthy donors up-regulated the frequency of COX-2+
cells in response to LPS (cancer group, p = 0.01; healthy
group, p = 0.02) and IFN-γ+LPS stimulation (cancer
group, p = 0.02; healthy group, p = 0.004) compared to
the respective unstimulated controls (data not shown).
There were no significant differences in IL-8 (Fig. 4B), IL-
10, and IL-12 (data not shown) secretion by cryopre-
served PBMC-derived MDDC from healthy donors com-
pared to cancer patients.
When tested for the ability to stimulate allogeneic CD4+ T
cells (Fig. 4C) and CD8+ T cells (data not shown), matureJournal of Immune Based Therapies and Vaccines 2007, 5:7 http://www.jibtherapies.com/content/5/1/7
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MDDC prepared from cryopreserved PBMC of cancer
patients (five breast cancer and two colon cancer patients)
were not significantly different from those of healthy
donors.
When the capacity of MDDC to stimulate autologous
CD4+ and CD8+ T cell proliferation was tested, all the
MDDC preparations derived from both cryopreserved
PBMC of healthy donors as well as cancer patients were
able to significantly enhance the antigen-specific (i.e.,
SEB, CMV-pp65, HER2/neu, and MAGE) response com-
pared to stimulation of PBMC with antigens alone. Figure
4C displays data of SEB-specific proliferation of CD4+
(middle graph) and CD8+ (bottom graph) T cells using
CFSE-labeled autologous PBMC. MDDC from healthy
donors as well as cancer patients stimulated higher CEA-
specific CD8+ T cell proliferation compared to stimulation
of PBMC with CEA alone.
When efficiency of autologous T cell stimulation was
compared between these two MDDC groups, there were
no statistically significant differences between the anti-
gen-specific (SEB, CMV-pp65, HER2/neu, and MAGE)
CD4+ as well as CD8+ T cell proliferation induced by anti-
gen-pulsed MDDC from these two groups (e.g. DC+SEB
columns of healthy vs. cancer groups in Fig. 4C). Histo-
Effect of maturation on MDDC derived from fresh PBMC of healthy donors (Fresh Healthy), cryopreserved PBMC of healthy  donors (Cryo. Healthy), and cryopreserved PBMC of cancer patients (Cryo. Cancer) Figure 2
Effect of maturation on MDDC derived from fresh PBMC of healthy donors (Fresh Healthy), cryopreserved 
PBMC of healthy donors (Cryo. Healthy), and cryopreserved PBMC of cancer patients (Cryo. Cancer). A. Sur-
face phenotype: Immature and mature MDDC from each of the three groups were compared for their expression levels (MFI) 
of CD86, CD83, and HLA-DR. B. Function: Immature and mature MDDC were cultured for additional 18–20 h in presence of 
BFA. Cells were processed and analyzed to evaluate the expression of intracellular IL-12 (% CD209+IL-12+) or COX-2 (% 
CD209+COX-2+). Quantities of secreted IL-8 by immature and mature MDDC from each of these two groups were detected 
by CBA assay of the culture supernatants collected on day 7. Bars in all the scatter plots represent medians. **, statistically sig-
nificant differences (P < 0.01); ***, statistically significant differences (P < 0.001).
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Intracellular detection of IL-12 and COX-2 in MDDC Figure 3
Intracellular detection of IL-12 and COX-2 in MDDC. The cells were stimulated (or not) and processed for flow cytom-
etry analysis as described in Methods.A. Dot plots in this panel show MDDC, gated on CD209+cells that express intracellular 
IL-12 in unstimulated and IFNγ+LPS-stimulated immature MDDC from fresh PBMC. B. Dot plots in this panel show intracellu-
lar staining of COX-2 in unstimulated and LPS stimulated immature MDDC from fresh PBMC.
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grams in Fig. 5 display typical proliferation of CD4+ T cells
(dilution of CFSE label) from DC+SEB-stimulated autolo-
gous PBMC of a healthy donor and a cancer patient.
Discussion
Careful manipulation of blood-derived DC precursors
using a cocktail of cytokines to generate DC-like cells in
vitro has been shown to generate efficient antigen-specific
T cell immune responses [42]. Advanced understanding of
the technologies required to generate human DC, load
DC with antigens of interest, and demonstrate a DC-
mediated cytotoxic T cell response has enabled the execu-
tion of a number of Phase I clinical cancer vaccine tri-
als[43,44]. However, lack of standardization of the source
of DC precursors (e.g., fresh vs. cryopreserved), and the
type of DC (e.g., immature vs. mature) utilized for therapy
make it difficult to compare the outcomes across trials in
order to develop better therapeutic strategies[45,46].
In the present report, monocytes were used as precursors
to generate DC because they do not require mobilization
and can generate enriched populations of DC in vitro in 7
Comparison of mature MDDC derived from cryopreserved PBMC of healthy donors vs. cancer patients Figure 4
Comparison of mature MDDC derived from cryopreserved PBMC of healthy donors vs. cancer patients. A. Sur-
face phenotype: Expression levels (MFI) of CD86, CD83, and HLA-DR on mature MDDC derived from healthy donors 
(healthy) were compared to those derived from cancer patients (cancer). B. Function: Mature MDDC from each group were 
cultured for additional 18–20 h in presence of BFA. Cells were processed and analyzed to evaluate the expression of intracel-
lular IL-12 (%CD209+IL-12+) or COX-2 (%CD209+COX-2+) as described earlier. Quantities of secreted IL-8 (pg/ml) by 
mature MDDC from each of these two groups were detected by CBA assay of the culture supernatants collected on day 7. C. 
T cell stimulation: The top scatter plot shows proliferation of allogeneic CD4+ T cells using mature MDDC from PBMC of 
healthy donors and cancer patients. The lower two scatter plots demonstrate enhancement of MDDC mediated SEB-specific 
autologous CD4+ and CD8+ T cell proliferation. Both allogeneic and autologous antigen-specific T cell stimulation assays were 
set up and percent proliferation was measured as described earlier. Bars in all the scatter plots represent medians. *, statisti-
cally significant differences (P < 0.05); **, statistically significant differences (P < 0.01).
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Enhancement of SEB-specific proliferation of autologous CD4+ T cells by mature MDDC Figure 5
Enhancement of SEB-specific proliferation of autologous CD4+ T cells by mature MDDC. Histograms in this figure 
show the CFSE staining profile of CD4+ T cells from cryopreserved PBMC stimulated with autologous DC pulsed with SEB (A) 
data from a representative healthy donor, and (B) data from a representative cancer patient. Proliferation of CD4+ T cells in 
presence of SEB alone was 3.1% (healthy donor) and 0.35% (cancer patient). Proliferation is measured as the percentage of 
cells showing decreased staining intensity of CFSE compared to the intensity of the CFSEbright population (marked as Peak 1 in 
all histograms). Numbers in all histograms represent %proliferation.
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days. The effect of cryopreservation on differentiation of
precursors into DC-like cells was assessed by performing a
cross-sectional comparison of MDDC derived from fresh
and cryopreserved PBMC of healthy donors. In addition,
cryopreserved PBMC-derived MDDC from cancer patients
were compared to cryopreserved PBMC-derived MDDC
from healthy donors to evaluate their phenotypic and
functional differences. The mature MDDC from cryopre-
served PBMC of healthy donors show reduced functional
ability compared to the fresh healthy group. However,
this observation could also be partially attributed to dif-
ferences in the donors used in these two groups. The
marker expression pattern of mature MDDC from cryop-
reserved PBMC of cancer patients is at least equivalent to
that associated with cryopreserved PBMC of healthy
donors.
MDDC generated from all three sources of precursors
were morphologically identical, being large in size and
having a round or oval nucleus (data not shown). The
number of CD209+ MDDC from cryopreserved PBMC of
healthy donors was higher, although not significantly,
when compared to that of cancer patients (data not
shown). However, the immature as well as mature cul-
tures from the cryopreserved healthy donor group con-
tained significantly higher numbers of CD209+  DC
compared to the fresh healthy donor group (immature
cells, 45.6% [cryopreserved] versus 13.6% [fresh], p <
0.01; mature cells, 53.8% [cryopreserved] versus 24.3%
[fresh], p < 0.01). These differences in yields could be due
to the effect of cryopreservation, or to blood sample col-
lection by CPT versus leukapheresis, or to differences in
donors used for this comparison.
Loss of CD14 expression is a characteristic feature of
mature MDDC. MDDC from all the three groups were
very low or negative (MFI and percent positive) in their
CD14 expression. Consistent with an earlier report, the
cytokine/PGE-2 maturation cocktail used in this study
provided strong maturation signals for cancer-patient
derived DC[15]. In the healthy donor group, CD86
expression was higher on cryopreserved PBMC-derived
MDDC compared to those derived from fresh PBMC. This
observation suggests that higher expression levels of
CD86 on cryopreserved PBMC-derived MDDC could be
related to non-specific activation due to components of
the freezing medium, such as albumin or DMSO, or the
freezing process itself. However, there were no significant
differences between CD86 expression on cryopreserved
PBMC-derived MDDC from the healthy donors and can-
cer patients. We also compared the expression of HLA-DR
and CD83, both of which are markers of activated and
mature DC. MDDC from cancer patients expressed signif-
icantly higher levels of HLA-DR and CD83 compared to
healthy donors (cryopreserved), confirming their acti-
vated and mature phenotype. This increased expression of
activation and/or maturation markers on MDDC gener-
ated from cryopreserved PBMC of healthy donors and
cancer patients is either endogenous condition or could
also be due to the uptake of dead cells that may be gener-
ated during the freezing/thawing and subsequent culture
process.
IL-12 and COX-2 were selected as markers to compare the
functional capacity of MDDC. The ability to produce IL-
12, which drives the Th1 helper T cell response, is consid-
ered to be one of the most important functions of DC
because IL-12 secretion appears to correlate with thera-
peutic efficacy in clinical trials [47-51]. In our study,
although there were no significant differences in the fre-
quency of IL-12+ mature MDDC from fresh versus cryop-
reserved PBMC of healthy donors, culture supernatants
from fresh PBMC-derived mature MDDC contained
higher levels of secreted IL-12 (range of 5–25 pg/mL/0.5
million cells). The fact that the actual levels of the secreted
cytokines were low may be related to the observation that
only 23%–54% of the heterogeneous cell population was
actually CD209+ DC. The low levels of secreted IL-12
could also be related to the presence of PGE-2 in the mat-
uration cocktail: PGE-2 is a potent inducer of IL-10 and an
inhibitor of IL-12 production by APC, including DC. In
our study, comparable amounts of IL-10 (median = 11.5
pg/ml) and IL-12 (median = 9.5 pg/ml) were secreted by
fresh PBMC-derived mature MDDC from healthy donors.
This observation differs from an earlier report showing the
absence of IL-12 and presence of IL-10 in cancer patient-
derived MDDC culture supernatants[5] and may be asso-
ciated with differences in the timing of addition of matu-
ration stimuli and harvest of DC culture supernatants.
Significantly higher frequencies of IL-12+  cells were
observed in mature MDDC cultures derived from cryopre-
served PBMC of cancer patients when compared to those
from cryopreserved PBMC of healthy donors. However,
actual IL-12 secretion by mature MDDC from these two
groups was below the limit of detection (<5 pg/ml). This
suggests that despite the use of cryopreserved PBMC as a
precursor source and the use of PGE-2 for maturation,
MDDC from cancer patients could nonetheless still pro-
duce intracellular IL-12.
COX-2 is over-expressed in a variety of pre-malignant and
malignant conditions. In spite of the demonstrated asso-
ciation of COX-2 with immuno-modulation of APC func-
tion in cancer, there are no reports comparing COX-2
expression in DC from healthy donors to those from can-
cer patients. Other studies have used mRNA expression,
immunohistochemistry, or western blot to detect COX-2
in various cells including DC [52-54]. Here, we report the
use of flow cytometry to detect COX-2 expressing DC in
response to inflammatory stimulation. Mature MDDCJournal of Immune Based Therapies and Vaccines 2007, 5:7 http://www.jibtherapies.com/content/5/1/7
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from cryopreserved PBMC of healthy donors contained
significantly lower numbers of COX-2+ cells compared to
those derived from fresh PBMC, indicating that cryop-
reservation of precursors may adversely affect some func-
tionality of mature MDDC. Mature MDDC derived from
cryopreserved PBMC of cancer patients, conversely,
showed a trend towards higher numbers of COX-2+ cells
compared to those derived from cryopreserved PBMC of
healthy donors, suggesting a more activated or inflamed
phenotype of cells from cancer patients. These cells may
be producing PGE-2 endogenously and thereby regulating
DC function, i.e., maturation and IL-12 production in vivo
[24,55]. It is of interest to note that when LPS-stimulated
MDDC were simultaneously stained for intracellular
expression of IL-12 and COX-2, about 50–80% of IL-12+
cells also expressed COX-2. Higher frequency of COX-2+
cells and lower amounts of IL-12 production by MDDC
matured in presence of PGE-2 may warrant further studies
to evaluate whether PGE-2 could be eliminated from mat-
uration cocktail.
Phenotypic and functional deficiencies and decreased in
vitro T cell stimulatory capacity of DC from patients with
chronic myeloid leukemia and breast cancer have been
reported [56, 57]. However, it is evident from our data
that the expression of co-stimulatory molecules and intra-
cellular functional markers relevant for T cell interaction
and activation are largely preserved in MDDC from cancer
patients. Consistent with these observations, MDDC in
our study were also able to stimulate both allogeneic and
antigen-specific autologous T cells. Our autologous T cell
stimulation results are in agreement with those reported
earlier for advanced breast cancer patients[5] and pancre-
atic carcinoma patients[12] but different from those
described for patients with operable or early stage breast
cancer [7, 14, 57]. The differences in these reports could
be related to the disease stage or the techniques used in
culturing the DC or measuring the response.
It is of interest that MDDC from healthy donors in our
study stimulated responses to several cancer antigens.
Fresh PBMC-derived DC-driven CD4+ T cell proliferation
in response to Her2/neu and CEA was significantly higher
compared to that driven by cryopreserved PBMC-derived
DC. Whereas there were no differences in the DC-driven
CD4+ T cell proliferative responses of these two groups to
SEB, pp65 and MAGE antigens. These results suggest that
healthy donors are able to make T cell responses to certain
cancer antigens, and some of these antigen-specific
responses are sensitive to cryopreservation. Cancer-anti-
gen-specific intracellular cytokine expression in T cells has
also been observed in a fresh PBMC healthy donor cohort
(M. Inokuma, manuscript in preparation). Not surpris-
ingly, the median T cell responses to DC pulsed with can-
cer antigens were higher in cancer patients compared to
those from healthy donors, although the difference was
not statistically significant. All of these observations indi-
cate that although cryopreservation affects some func-
tional responses in healthy donors, which could be
partially attributed to differences in the donor pool,
MDDC from cancer patients are at least as functionally
equivalent as those from healthy donors. It is important
to note that although the cancer patient cohort used in
this study consisted of breast, colon, and lung cancers, the
characteristics of the MDDC did not appear to segregate
based on the type of cancer. Thus, for example, MDDC
from breast cancer patients behaved similarly to those
from colon cancer patients. However, a larger number of
patients may be required to investigate any cancer-specific
differences.
Although altered DC function and differentiation have
been proposed as a fundamental mechanism by which
tumors evade the immune system, DC from the cancer
patients used in the present study appear to possess basic
functionality associated with generating efficient T cell
responses. The failure of immune surveillance in these
patients may more likely be associated with the tumoral
environment than with DC functional capacity itself.
Thus, tumor-derived immunosuppressive factors, such as
vascular endothelial growth factor [58, 59], PGE-2[54],
spermine [6], and mechanisms such as apoptosis of DC
and T cells [60, 61], Fas/FasL interaction [62], TLR-4 medi-
ated resistance of tumor cells to CTL attack [63], as well as
defective maturation of hematopoetic cells [64] may
obstruct effective in vivo immune responses by inhibiting
endogenous DC function. This suggests that the negative
influence of endogenously-growing tumors on DC func-
tion may be partially responsible for the mixed success of
clinical trials reported so far. Increased understanding of
tumor-host interactions may help uncover these phenom-
ena and allow better harnessing of the immune system for
effective cancer immunotherapy.
Conclusion
Our data suggest that monocytes from cryopreserved
PBMC of cancer patients can be fully differentiated into
mature DC with the phenotype and function similar to or
better than those derived from healthy donors. The appar-
ent inability of these patients to mount an effective
immune response against their tumor antigens seems to
be not necessarily related to defective DC phenotype. Fur-
thermore, autologous in vitro differentiated DC from cry-
opreserved PBMC of cancer patients may be a viable
option for immunotherapy.
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